We are entering an era of rapidly evolving transformation in cancer treatment as it relates to drug development, and a shifting paradigm of standardized health care in which detailed genetic and molecular information regarding a patient’s cancer is being used for personalized precision treatments.
Cambridge, MA, Feb. 8, 2018
We are entering an era of rapidly evolving transformation in cancer treatment as it relates to drug development, and a shifting paradigm of standardized health care in which detailed genetic and molecular information regarding a patient’s cancer is being used for personalized precision treatments.
In the fight against cancer, clinical-outcome focused precision oncology products represent an increasingly important therapeutic approach. These biopharmaceuticals are designed to maximize the therapeutic index of cytotoxic small-molecule drugs through their selective delivery to tumor cells while leaving normal, healthy cells untouched.
Product development represents a major obstacle to delivering these new therapies to patients. The current development processes are siloed, expensive and time consuming, making it operationally inefficient. The industry is striving to streamline operations, reduce timelines, and minimize risk. OncoBindi Therapeutics has developed an early asset development technology for fast-track “candidate to clinical product” approach using a series of platform technologies to provide a lead candidate rapidly to clinic.
This approach includes the use of OncoBindi Therapeutics’ NanoBindi™ platform for near real-time product development for the manufacturing of the precision therapeutic based on functional fabric based clinical interfaces. From selection of the cancer specific targeting ligand, protection from host defense, on demand controlled release and other clinical functionality can be manufactured in laboratory-scale quantities within four weeks.
Similarly, the chemistry for a range of clinical interfaces and functionality can be optimized, and developmental material can be produced within two weeks. Finally, a clinical viability risk assessment can provide both a lead candidate and related “prior knowledge” in line with the QbD paradigm within another six to eight weeks. The overall outcome represents time, cost, and resource savings in the development of a precision oncology product.
Contact Person:
OncoBindi Therapeutics
Ms. Jenny Smith VP, Corporate Development
Phone: 857-259-4272
communications@oncobindi.com
